Exelixis, Inc. (EXEL)

Market Cap	8.22B
Revenue (ttm)	2.01B
Net Income (ttm)	349.99M
Shares Out	285.25M
EPS (ttm)	1.14
PE Ratio	25.23
Forward PE	22.79
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,683,255
Open	28.59
Previous Close	28.66
Day's Range	28.38 - 29.03
52-Week Range	19.12 - 29.75
Beta	0.54
Analysts	Buy
Price Target	29.93 (+3.82%)
Earnings Date	Oct 29, 2024

About EXEL

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF recep...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 7, 2000
• Employees: 1,310
• Stock Exchange: NASDAQ
• Ticker Symbol: EXEL
• Website: https://www.exelixis.com

Financial Performance

In 2023, Exelixis's revenue was $1.83 billion, an increase of 13.60% compared to the previous year's $1.61 billion. Earnings were $207.77 million, an increase of 13.98%.

Analyst Forecast

According to 14 analysts, the average rating for EXEL stock is "Buy." The 12-month stock price forecast is $29.93, which is an increase of 3.82% from the latest price.

Price Target

$29.93

(3.82% upside)

Analyst Consensus: Buy